Share

2011 EORTC Symposium on Quality of life, Symptom Research, and Patient Reported Outcomes in Cancer Clinical Trials

The 2nd EORTC Symposium on Quality of life, Symptom Research, and Patient Reported Outcomes in Cancer Clinical Trials will be held 7-9 September 2011 at the European Parliament. The backing of the European Parliament demonstrates the commitment and appreciation of the public sector for the valuable research conducted by the EORTC, and for the EORTC’s mission to to improve the management of cancer and related problems by increasing survival but also patient quality of life.

This symposium will address recent developments in EORTC tools as well as other measures for use in clinical trials, but will also have a broader focus including discussion of international developments and research in oncology. The members of the faculty are international key opinion leaders in their fields who will be able to provide a diverse view on health related quality of life (HRQOL). Participants will learn aspects of design, conduct, and analysis of HRQOL in cancer clinical trials.

A prominent role will be played by representatives from the European Cancer Patient Coalition, representing more than 300 cancer patient groups from 42 countries, who will provide insight from the perspective of the cancer patient. Moreover, collaboration with Marisa Matias, Member of the European Parliament from Portugal and chair of the Forum Against Cancer Europe (FACE), will contribute further to the development of a successful dialogue between the various stakeholders.

A substantial level of support is being provided to make attendance at this symposium possible for a broader audience: registration for students is free, and 30 fellowships of up to 400€ are available for young academics (under 35 years old), advanced clinical students, or persons from developing countries.

Attendees are encouraged to subscribe as soon as possible as places are limited.

Registration for this symposium can be done online via the PROBE website: www.eortc.be/probe/

John Bean

Back to news list

Related News

  • EORTC: Advancing research and treatment for rare cancers

  • EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration

  • Appointment of Malte Peters as EORTC Strategic Alliance Officer

  • Unique series of workshops in partnership with the European Medicines Agency (EMA)

  • EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)

  • Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023

  • EORTC Quality of Life measures integrated in CDISC

  • EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma

  • Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia

  • New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023